Table 2 Prognostic factors of PFS in 141 patients with early-stage disease from the training set and 69 patients in the validation set.
Progression-free survival
Discovery
set (n = 141)
Validation
set (n = 69)
HR95% CIPHR95% CIP
TCF of >25%4.92.5–9.7<0.001103.4–31<0.001
Stage (IB versus IA)2.51.3–4.90.0086.41.5–280.01
Presence of plaques2.21.1–4.20.021.90.8–4.40.15
Elevated LDH levels1.20.4–3.10.81.00.3–3.41
Large-cell transformation1.50.4–6.40.61.60.2–120.6
Age (>60 years)2.01.0–3.70.041.30.5–3.00.6
CLIPI score*
Intermediate risk (versus low)2.21.0–5.00.050.40.1–2.00.2
High risk (versus low)3.51.6–7.70.0022.30.9–5.90.07

*The CLIPI was calculated on the basis of the presence of the following factors: age (>60 years), male sex, plaques, folliculotropism, and clinical adenopathy N1/Nx; low risk = 0 to 1, intermediate risk = 2, and high risk = 3 to 5 prognostic factors.